<DOC>
	<DOCNO>NCT00433407</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood patient cancer laboratory may help doctor predict well patient respond treatment . It may also help study cancer future . PURPOSE : This laboratory study look blood sample patient receive trastuzumab and/or chemotherapy HER2-positive solid tumor ass T-cell response .</brief_summary>
	<brief_title>T-Cell Response Patients Receiving Trastuzumab and/or Chemotherapy HER2-Positive Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : - Assess T-cell activation blood sample patient receive trastuzumab ( Herceptin® ) and/or chemotherapy HER2-positive solid tumor . OUTLINE : Blood sample collect patient baseline day 21 , 42 , 84 trastuzumab ( Herceptin® ) /chemotherapy . Patients may contact 3-6 month completion trastuzumab/chemotherapy donate another blood specimen . Blood sample examine T-cell proliferation intracellular cytokine production . CD8 T-cell response , HER2/neu-specific antibody titer , skin hypersensitivity test response also measure . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis solid epithelial tumor , include , limited , follow : Breast cancer Ovarian cancer Lung cancer Uterine cancer Prostate cancer HER2/neupositive disease immunohistochemistry fluorescent situ hybridization Must receive trastuzumab ( Herceptin® ) and/or chemotherapy ( e.g. , paclitaxel , docetaxel , fluorouracil , estramustine ) PATIENT CHARACTERISTICS : Absolute neutrophil count &gt; 1,000/mm^3 Absolute lymphocyte count &gt; 400/mm^3 Platelet count &gt; 90,000/mm^3 Hemoglobin &gt; 8 g/dL PRIOR CONCURRENT THERAPY : No chemotherapy within past 4 week</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I uterine sarcoma</keyword>
	<keyword>stage II uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
</DOC>